J. Mezger

4.8k total citations · 2 hit papers
53 papers, 3.4k citations indexed

About

J. Mezger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J. Mezger has authored 53 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in J. Mezger's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (13 papers) and Cancer therapeutics and mechanisms (6 papers). J. Mezger is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (13 papers) and Cancer therapeutics and mechanisms (6 papers). J. Mezger collaborates with scholars based in Germany, United States and United Kingdom. J. Mezger's co-authors include Joachim von Pawel, Martin Reck, Rodryg Ramlau, Petr Zatloukal, Vera Hirsh, Venice Archer, Christian Manegold, N. Moore, Natasha B. Leighl and Vera Gorbounova and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J. Mezger

50 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

2009 1.2k citations Martin Reck, Joachim von Pawel et al. profile →
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

2010 498 citations Martin Reck, Joachim von Pawel et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Mezger Germany	18	1.9k	1.7k	746	541	451	53	3.4k
Alessandra Bearz Italy	31	2.5k 1.3×	3.1k 1.8×	772 1.0×	369 0.7×	284 0.6×	176	4.4k
Jacob D. Bitran United States	32	1.5k 0.8×	1.1k 0.6×	462 0.6×	334 0.6×	578 1.3×	138	3.0k
Andreas Schalhorn Germany	26	1.8k 1.0×	811 0.5×	617 0.8×	699 1.3×	255 0.6×	93	3.0k
Marco Alloisio Italy	36	1.7k 0.9×	3.0k 1.8×	884 1.2×	843 1.6×	405 0.9×	157	4.6k
Feng‐Hua Wang China	31	1.5k 0.8×	861 0.5×	872 1.2×	637 1.2×	331 0.7×	126	2.9k
Shaodong Hong China	28	2.9k 1.5×	1.8k 1.1×	619 0.8×	463 0.9×	307 0.7×	128	3.9k
Carlo Barone Italy	31	2.3k 1.2×	1.4k 0.8×	769 1.0×	671 1.2×	461 1.0×	130	3.6k
Antoine Thyss France	32	1.7k 0.9×	885 0.5×	783 1.0×	509 0.9×	695 1.5×	111	3.5k
Gerasimos Aravantinos Greece	36	2.3k 1.2×	1.2k 0.7×	975 1.3×	1.3k 2.4×	428 0.9×	205	4.5k
H. Au Canada	13	2.9k 1.5×	1.1k 0.6×	681 0.9×	486 0.9×	180 0.4×	23	3.5k

Countries citing papers authored by J. Mezger

Since Specialization

Citations

This map shows the geographic impact of J. Mezger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Mezger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Mezger more than expected).

Fields of papers citing papers by J. Mezger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Mezger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Mezger. The network helps show where J. Mezger may publish in the future.

Co-authorship network of co-authors of J. Mezger

This figure shows the co-authorship network connecting the top 25 collaborators of J. Mezger. A scholar is included among the top collaborators of J. Mezger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Mezger. J. Mezger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ciuleanu, Tudor–Eliade, Samreen Ahmed, Joo-Hang Kim, et al.. (2017). Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. British Journal of Cancer. 117(6). 757–766. 28 indexed citations

Reck, Martin, Michael Thomas, Cornelia Kropf-Sanchen, et al.. (2016). Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE). Oncology Research and Treatment. 39(9). 539–547. 9 indexed citations

Natale, Ronald B., Fiona Blackhall, Dariusz M. Kowalski, et al.. (2014). Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. Journal of Thoracic Oncology. 9(11). 1704–1708. 30 indexed citations

Leighl, Natasha B., Petr Zatloukal, J. Mezger, et al.. (2010). Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL). Journal of Thoracic Oncology. 5(12). 1970–1976. 82 indexed citations

Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2010). Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology. 21(9). 1804–1809. 498 indexed citations breakdown →

Heim, M.U., et al.. (2008). Austauschtransfusion und (oder) Plasmapherese: wirksame Maßnahmen bei der schweren Malaria tropica?. DMW - Deutsche Medizinische Wochenschrift. 113(23). 941–944.

Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2007). C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S360–S361. 6 indexed citations

Manegold, C., et al.. (2005). Combination of a Toll-like receptor 9 (TLR9) agonist, CPG 7909 (CPG) with first line taxane/platinum improves response rate in late stage non-small-cell lung cancer (NSCLC). mediaTUM (Technical University of Munich). 2 indexed citations

Manegold, Christian, et al.. (2005). Randomized Multicenter Phase II Study of Gemcitabine Versus Docetaxel as First-Line Therapy with Second-Line Crossover in Advanced-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 7(3). 208–214. 6 indexed citations

10.

Gralla, Richard J., M. Lichinitser, S. van der Vegt, et al.. (2003). Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Annals of Oncology. 14(10). 1570–1577. 367 indexed citations

11.

Rummel, Mathias, Kai Uwe Chow, T. Karakas, et al.. (2002). Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. European Journal of Cancer. 38(13). 1739–1746. 35 indexed citations

12.

Mezger, J., et al.. (1999). Possible Role of FDG-PET in the Early Prediction of Therapy Outcome in Liver Metastases of Colorectal Cancer. Hybridoma. 18(1). 87–91. 30 indexed citations

13.

Glasmacher, Axel, Ernst Molitor, Christian Hahn, et al.. (1998). Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia. 12(9). 1338–1343. 48 indexed citations

14.

Gorschlüter, Marcus, Axel Glasmacher, F. Risse, et al.. (1997). Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient. Nephrology Dialysis Transplantation. 12(3). 593–595. 6 indexed citations

15.

Drechsler, S., U. Bruntsch, Markus Bangerter, et al.. (1997). Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Supportive Care in Cancer. 5(5). 387–395. 13 indexed citations

16.

Issing, W. J., T. P. U. Wustrow, R. Oeckler, J. Mezger, & Michael Nerlich. (1993). An association of the RB gene with osteosarcoma: molecular genetic evaluation of a case of hereditary retinoblastoma. European Archives of Oto-Rhino-Laryngology. 250(5). 277–80. 9 indexed citations

17.

Bauchinger, M. & J. Mezger. (1990). A case of malignant mastocytosis with near-haploid, near-diploid, and polyploid cells in the bone marrow. Cancer Genetics and Cytogenetics. 48(1). 13–21. 12 indexed citations

18.

Liewald, F., L. Sunder-Plassmann, Hendrik Dienemann, & J. Mezger. (1989). Das Pleuramesotheliom ? Probleme in der Diagnostik und klinischer Verlauf bei 25 Patienten. Langenbeck s Archives of Surgery. 374(2). 105–110. 2 indexed citations

19.

Mezger, J., et al.. (1988). Elevated Serum CA 125 Levels in Patients with Benign Ascitic or Pleural Effusions. Tumor Biology. 9(1). 47–52. 15 indexed citations

20.

Mezger, J., R. Lamerz, H Arnholdt, D. Huhn, & W. Wilmanns. (1986). Tumormarker in der Diagnostik von Aszites- und Pleurapunktaten. Oncology Research and Treatment. 9(1). 11–16. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact